Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience
暂无分享,去创建一个
A. Bertozzi | L. Massacesi | V. Damato | A. Mariottini | A. Repice | C. Mechi | A. Barilaro | Riccardo Nistri | L. Marchi | Maria Di Cristinzi
[1] B. Escribano,et al. SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19 , 2022, Journal of Neurology.
[2] J. Al-Tawfiq,et al. Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines , 2022, Infection and drug resistance.
[3] A. Copas,et al. Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study , 2022, The Lancet Healthy Longevity.
[4] M. Inglese,et al. Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients , 2022, Multiple sclerosis.
[5] F. Mastroianni,et al. SARS-CoV-2 antibody response after BNT162b2 mRNA vaccine in healthcare workers: Nine-month of follow-up , 2022, Vaccine: X.
[6] A. Bertozzi,et al. Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis , 2022, Journal of Neurology.
[7] M. Massari,et al. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study , 2022, BMJ.
[8] P. Moss. The T cell immune response against SARS-CoV-2 , 2022, Nature Immunology.
[9] O. A. Ogun,et al. Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study , 2022, The Lancet Regional Health - Americas.
[10] A. Achiron,et al. COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose , 2022, Journal of the Neurological Sciences.
[11] C. Bassetti,et al. Multiple Sclerosis immunotherapies and COVID-19 mortality: an analysis of the FDA Adverse Event Reporting System , 2022, Therapeutic advances in neurological disorders.
[12] V. Di Lazzaro,et al. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies , 2021, Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.
[13] A. ten Brinke,et al. Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate? , 2021, Multiple Sclerosis and Related Disorders.
[14] V. Tomassini,et al. mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.
[15] T. Fiolet,et al. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review , 2021, Clinical Microbiology and Infection.
[16] M. Ulivelli,et al. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies , 2021, EBioMedicine.
[17] E. Wherry,et al. Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. , 2021, medRxiv.
[18] C. Oreja-Guevara,et al. Risk and outcomes of COVID‐19 in patients with multiple sclerosis , 2021, European journal of neurology.
[19] C. Louapre,et al. Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination? , 2021, Multiple sclerosis.
[20] A. Achiron,et al. COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021 , 2021, Multiple sclerosis.
[21] A. Lascano,et al. Risk of MS relapse after yellow fever vaccination , 2020, Neurology: Neuroimmunology & Neuroinflammation.
[22] A. Jawad,et al. Rituximab-Treated Patients Have a Poor Response to Influenza Vaccination , 2013, Journal of Clinical Immunology.
[23] J. Correale,et al. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. , 2011, Archives of neurology.
[24] Jeffrey A. Cohen,et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.
[25] A. Compston,et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.
[26] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.